Anteris Technologies Raises $200 Million to Advance Aortic Stenosis Treatment with Strategic Medtronic Partnership
核心洞察
Anteris Technologies (搜索) completed a $200 million public offering at $5.75 per share to fund its DurAVR (搜索) transcatheter heart valve development program.
Medtronic made a strategic investment of up to $90 million through a private placement, acquiring 16-19.99% ownership stake in the structural heart company.
The funding will support the ongoing PARADIGM Trial for the biomimetic DurAVR (搜索) valve system targeting patients with severe aortic stenosis (搜索).
Anteris Technologies (搜索) Global Corp. successfully completed a $200 million public offering on January 20, 2026, pricing 34,782,609 shares at $5.75 per share to advance its innovative transcatheter heart valve program for treating aortic stenosis (搜索). The structural heart company also secured a strategic partnership with Medtronic plc, which committed to investing up to $90 million through a concurrent private placement.
Strategic Partnership with Medtronic
Under the stock purchase agreement dated January 20, 2026, Medtronic will acquire between 16.0% and 19.99% of Anteris' outstanding shares following the completion of the public offering. The medical device giant's investment at the same $5.75 per share price signals strong confidence in Anteris' technology platform and commercial potential.
Wells Fargo Securities served as the sole placement agent for Medtronic's private investment, while Barclays, Wells Fargo Securities, and Cantor acted as joint book-running managers for the public offering. The offering is expected to close on January 22, 2026, subject to customary closing conditions.
Funding Clinical Development and Manufacturing Expansion
Anteris intends to deploy the combined proceeds from both the public offering and Medtronic's strategic investment to support several key initiatives. The primary focus will be advancing the PARADIGM Trial (NCT07194265), a global pivotal study evaluating the safety and efficacy of the DurAVR (搜索) Transcatheter Heart Valve in patients with severe aortic stenosis (搜索).
The company also plans to expand its manufacturing capabilities and fund ongoing research and development activities for v2vmedtech, inc., with remaining proceeds allocated to working capital and general corporate purposes.
Revolutionary Biomimetic Valve Technology
The DurAVR (搜索) THV represents a significant technological advancement in transcatheter aortic valve (搜索) replacement. Developed in collaboration with leading interventional cardiologists and cardiac surgeons, the balloon-expandable valve is designed as the first biomimetic valve that mimics the performance of a healthy human aortic valve to replicate normal aortic blood flow.
The valve system incorporates Anteris' proprietary ADAPT (搜索) anti-calcification tissue technology, which has received FDA clearance and has been used clinically for over 10 years. This proven technology has been distributed for use in more than 55,000 patients worldwide, providing a substantial clinical foundation for the DurAVR (搜索) platform.
Clinical Progress and Market Opportunity
The PARADIGM Trial has already achieved its first patient enrollments and implantations in Denmark during the fourth quarter of 2025, marking a critical milestone in the development program. The trial is designed to evaluate the DurAVR (搜索) THV System, which comprises the DurAVR valve, ADAPT (搜索) tissue, and the balloon-expandable ComASUR Delivery System.
Aortic stenosis (搜索) represents a significant unmet medical need as a potentially life-threatening condition resulting from the narrowing of the aortic valve (搜索). The biomimetic design approach of the DurAVR (搜索) valve aims to address limitations of current transcatheter valve technologies by more closely replicating natural valve function.
The successful completion of this financing round, combined with Medtronic's strategic investment, positions Anteris to accelerate its clinical development timeline and advance toward potential regulatory approval for this innovative treatment option for patients with severe aortic stenosis (搜索).